Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

A 61-year-old man allegedly stabbed Sunday night by his 26-year-old son in Pearl City told police his son suffers from ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Many currently available schizophrenia drugs work by blocking dopamine type 2 (D2) receptors. But these drugs offer limited efficacy while introducing side effects that make it hard for patients ...

High dropout rates are typical in schizophrenia drug studies. Finding a drug that works can be a long ordeal punctuated by crises and hospitalizations. Side effects of existing medications ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...